An evaluation framework for funding drugs for rare diseases

Value in Health

Volumn 15, Issue 6, 2012, Pages 982-986

  Winquist, Eric ^a   Bell, Chaim M ^b,c   Clarke, Joe T R ^d,e   Evans, Gerald ^f   Martin, Janet ^a   Sabharwal, Mona ^g   Gadhok, Anita ^g   Stevenson, Helen ^g   Coyle, Doug ^h  

^a WESTERN UNIVERSITY   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

^h UNIVERSITY OF OTTAWA   (Canada)

Author keywords

cost effectiveness; drug reimbursement; glycogen storage disease; health policy; mucopolysaccharidosis

Indexed keywords

IDURONATE 2 SULFATASE;

ARTICLE; CANADA; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONCEPTUAL FRAMEWORK; DRUG MANUFACTURE; DRUG SCREENING; EVALUATION; FUNDING; HEALTH CARE POLICY; HUNTER SYNDROME; INFORMED CONSENT; PRIORITY JOURNAL; RARE DISEASE;

ADVISORY COMMITTEES; DRUG EVALUATION; ENZYME REPLACEMENT THERAPY; HEALTH POLICY; HUMANS; IDURONATE SULFATASE; INSURANCE, HEALTH, REIMBURSEMENT; MODELS, THEORETICAL; MUCOPOLYSACCHARIDOSIS II; ONTARIO; PHARMACEUTICAL PREPARATIONS; POLICY MAKING; RARE DISEASES; RESEARCH SUPPORT AS TOPIC; TREATMENT OUTCOME;

EID: 84866354190     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.06.009     Document Type: Article

References (20)

1. G. Miller The world's most expensive drugs FiercePharma Manufacturing http://www.fiercepharmamanufacturing.com/pages/chart-worlds-most-expensive- drugs March 2, 2010 [Accessed April 18, 2010]
2. J.T.R. Clarke, D. Amato, R.B. Deber Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario CMAJ 165 2001 595 596
3. C. Saltel Hunter's syndrome becomes the hunted Vue Weekly May 16, 2007 Issue #604 http://www.vueweekly.com/article.php?id=6277 [Accessed April 18, 2010]
4. Policy Research Division Strategic Policy Directorate Population and Public Health, Health Canada Economic burden of illness in Canada, 1998 www.phac-aspc.gc.ca/publicat/ebic-femc98/pdf/ebic1998.pdf [Accessed November 4, 2009]
5. J.W. Dear, P. Lilitkarntakul, D.J. Webb Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products Br J Clin Pharmacol 62 2006 264 271
6. CEDAC final recommendation and reasons for recommendation: idursulfase (Elaprase TM - Shire human Genetics Therapies, Inc.) http://www.cadth.ca/media/ cdr/complete/cdr-complete-Elaprase-Dec-19-2007.pdf [Accessed April 11, 2010]
7. Ontario Ministry of Health and Long-Term Care www.health.gov.on.ca/ english/public/program/drugs/drugs-ep.html [Accessed November 4, 2009]
8. L. Priest When an orphan drug is a patient's only hope The Globe and Mail http://www.theglobeandmail.com/news/national/article678958.ece April 13, 2008 [Accessed April 18, 2010]
9. N. Daniels, J. Sabin Setting limits fairly: can we learn to share medical resources 2002 Oxford University Press Oxford, UK
10. 107th Congress Public Law 280 Rare Diseases Act of 2002 http://www.gpo.gov/fdsys/pkg/PLAW-107publ280/html/PLAW-107publ280.htm [Accessed May 12, 2012]
11. J. Verweij, P.G. Casali, J. Zalcberg Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 2004 1127 1134
12. G.D. Demetri, A.T. van Oosterom, C.R. Garrett Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338
13. R.L. Prentice Surrogate endpoints in clinical trials: definition and operational criteria Stat Med 8 1989 431 440
14. T.R. Fleming, D.L. DeMets Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 125 1996 605 613
15. A. Bradford Hill The environment and disease: association or causation? Proc Royal Soc Med 58 1965 295 300
16. R. Martin, M. Beck, C. Eng Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome) Pediatrics 121 2008 e377 e386
17. F.A. Sonnenberg Introduction to decision theory and utilities M.J. Staquet, R.D. Hays, P.M. Fayers, Quality of Life Assessment in Clinical Trials: Methods and Practice 1998 Oxford University Press, Inc. New York
18. Ontario Public Drug Programs Exceptional Access Program Elaprase (idursulfase) - Reimbursement Guidelines Version 2 - October, 2009 http://www.health.gov.on.ca/english/providers/program/drugs/pdf/ elaprase-reimburse.pdf [Accessed 11, 2010]
19. D.A. Hughes, B. Tunnage, S.T. Yeo Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM 98 2005 829 836
20. A. Burls, D. Austin, D. Moore Commissioning for rare diseases: view from the frontline BMJ 331 2005 1019 1021